CSF3 and Decreased total neutrophil count: While AZD2811 antitumour activity appears limited, it is possible that enhanced efficacy could be achieved at higher doses; however, it is not feasible to assess this due to dose-limiting neutropenia, even in the presence of G-CSF prophylaxis.